NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting
Poster discussion will highlight anti-tumor activities of NT-I7 combined with pembrolizumab in heavily pretreated patients for whom checkpoint inhibitors are usually ineffective
ROCKVILLE, Md.–(BUSINESS WIRE)–April 27, 2022–NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announced it will present new clinical data for its lead asset NT-I7 (efineptakin alfa) across three presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago, June 3-7, 2022. These include one poster discussion and two poster displays.
Dr. Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech said: “We are pleased that the ASCO Scientific Program Committee selected our abstract on the efficacy and safety of NT-I7 in combination with pembrolizumab for a poster discussion. While the abstract was based on data cutoff as of January 14, 2022, the actual Phase 2a data presented and discussed at the congress will have a few additional months of follow-up. They will shed new light on the benefit of combining NT-I7 with a checkpoint inhibitor (CPI) in patients with immune-cold microsatellite stable colorectal cancer or pancreatic cancer and in those who progressed on previous CPI treatment. We are also excited to report progress made with NT-I7 administration after CAR-T infusion, another important area of potential NT-I7 use.”
NIT presentations at 2022 ASCO Annual Meeting:
| Primary Author | Abstract Title | Presentation details |
| Naing, A | Efficacy and Safety of NT-I7, Long-Acting Interleukin-7, plus Pembrolizumab in patients with advanced solid tumors: results from the Phase 2a study | Abstract #2514Poster discussion Session: Developmental Therapeutics -ImmunotherapyJune 5, 2022 11:30 AM-1:00 PM; 8:00 AM-11:00 AM CDT |
| Gastman, B | A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD- 1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report. | Abstract #9561Poster display Session: Melanoma/Skin CancersJune 6, 2022 1:15 PM-4:15 PM CDT |
| Ghobadi, A | Trial in Progress: A phase 1b study evaluating the safety, tolerability and preliminary anti- tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B- cell lymphoma | Abstract # TPS7596Poster display – Trial in progress (TiP) Poster Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic LeukemiaJune 4, 2022 8:00 AM- 11:00 AM CDT |
About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.
About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.
Forward-looking Statements
The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the “Company”) that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company’s control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.
Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties, and is subject to change based on various factors.
Contacts
Media Enquiries:
Hayley Jayawardene
+44 (0)7813 346395 / [email protected]
Investors:
Hayoung Lee
+82 31 709 5858 / [email protected]
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
